1st Quarter - Termination
KING & SPALDING LLP for AMARIN PHARMA, INC.
Firm
Client
Income
$30,000
Expenses
—
Terminated
Mar 31, 2022
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocacy related to cardiovascular health and reduction of residual risk after statins
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017) |
| DAVID JOSEPH FARBER | — |
| ALLISON F KASSIR | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.